From the ∗Kirby Institute
†School of Population Health, Faculty of Medicine and Health, UNSW Sydney
‡Westmead Clinical School, Faculty of Medicine and Health
§Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney
¶Western Sydney Sexual Health Centre, Western Sydney Local Health District
∥Centre for Social Research in Health, UNSW Sydney, Sydney, Australia
Acknowledgments: The authors would like to thank all the participants of the study, and the collaborating organizations ACON and the Centre for Social Research in Health. The PrEP in NSW Transition Study was supported by funds from the NSW Ministry of Health.
Conflict of Interest and Sources of Funding: A.E.G. has received an honorarium from MSD (2021) and research support from Glaxo Smith Kline (2021–2023) and ViiV Healthcare (2022–2023). A.E.H. has received honoraria from MSD (2022) and Pfizer (2021). B.R.B. has received honoraria from Gilead Sciences (2020) and ViiV Healthcare (2022), and is currently receiving unrestricted research grants from Gilead Sciences (2021–2022) and ViiV Healthcare (2022–2023). For the remaining authors, none were declared.
The Kirby Institute and Centre for Social Research in Health receive funding from the Australian Government Department of Health. The PrEP in NSW Transition Study was supported by funds from the NSW Ministry of Health. No pharmaceutical grants were received for this study.
Ethics: Approved by the Human Research Ethics Committee of UNSW Sydney (ethics approval number HC180411).
Off-Label Use/Unapproved Drugs or Products Statement: Doxycycline is not labeled for use as sexually transmitted infection preexposure prophylaxis or sexually transmitted infection postexposure prophylaxis.
Correspondence: Benjamin R. Bavinton, PhD, The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia. E-mail: [email protected].
Received for publication August 9, 2022, and accepted October 24, 2022.
